Northern Trust Corp Syndax Pharmaceuticals Inc Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Northern Trust Corp holds 737,606 shares of SNDX stock, worth $9.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
737,606
Previous 696,729 5.87%
Holding current value
$9.65 Million
Previous $14.3 Million 0.73%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$17.93 - $24.81 $732,924 - $1.01 Million
40,877 Added 5.87%
737,606 $14.2 Million
Q2 2024

Aug 14, 2024
SELL
$18.82 - $23.79 $848,744 - $1.07 Million
-45,098 Reduced 6.08%
696,729 $14.3 Million
Q1 2024

May 14, 2024
BUY
$19.71 - $24.57 $1.26 Million - $1.57 Million
63,722 Added 9.4%
741,827 $17.7 Million
Q4 2023

Feb 13, 2024
BUY
$11.39 - $21.67 $484,986 - $922,708
42,580 Added 6.7%
678,105 $14.7 Million
Q3 2023

Nov 13, 2023
SELL
$14.52 - $21.77 $420,237 - $630,067
-28,942 Reduced 4.36%
635,525 $9.23 Million
Q2 2023

Aug 11, 2023
BUY
$19.35 - $22.31 $1.35 Million - $1.55 Million
69,543 Added 11.69%
664,467 $13.9 Million
Q1 2023

May 15, 2023
BUY
$20.66 - $28.98 $946,909 - $1.33 Million
45,833 Added 8.35%
594,924 $12.6 Million
Q4 2022

Feb 13, 2023
BUY
$20.64 - $26.24 $931,462 - $1.18 Million
45,129 Added 8.95%
549,091 $14 Million
Q3 2022

Nov 14, 2022
BUY
$18.51 - $24.79 $297,066 - $397,854
16,049 Added 3.29%
503,962 $12.1 Million
Q2 2022

Aug 12, 2022
BUY
$13.64 - $19.48 $22,983 - $32,823
1,685 Added 0.35%
487,913 $9.39 Million
Q1 2022

May 13, 2022
BUY
$14.84 - $22.15 $483,071 - $721,026
32,552 Added 7.18%
486,228 $8.45 Million
Q4 2021

Feb 08, 2022
SELL
$15.23 - $22.47 $68,535 - $101,115
-4,500 Reduced 0.98%
453,676 $9.93 Million
Q3 2021

Nov 15, 2021
SELL
$13.87 - $19.8 $10,555 - $15,067
-761 Reduced 0.17%
458,176 $8.76 Million
Q2 2021

Aug 13, 2021
BUY
$13.42 - $25.18 $1.25 Million - $2.35 Million
93,451 Added 25.57%
458,937 $7.88 Million
Q1 2021

May 12, 2021
BUY
$19.28 - $24.59 $341,487 - $435,538
17,712 Added 5.09%
365,486 $8.17 Million
Q4 2020

Feb 11, 2021
BUY
$15.1 - $26.44 $103,646 - $181,484
6,864 Added 2.01%
347,774 $7.74 Million
Q3 2020

Nov 16, 2020
SELL
$13.39 - $17.48 $185,304 - $241,905
-13,839 Reduced 3.9%
340,910 $5.03 Million
Q2 2020

Aug 14, 2020
BUY
$8.94 - $20.98 $707,457 - $1.66 Million
79,134 Added 28.71%
354,749 $5.26 Million
Q1 2020

May 14, 2020
BUY
$6.65 - $12.03 $226,538 - $409,813
34,066 Added 14.1%
275,615 $3.02 Million
Q4 2019

Feb 14, 2020
SELL
$5.43 - $9.22 $11,750 - $19,952
-2,164 Reduced 0.89%
241,549 $2.12 Million
Q3 2019

Nov 13, 2019
BUY
$7.47 - $10.76 $415,563 - $598,589
55,631 Added 29.58%
243,713 $1.82 Million
Q2 2019

Aug 13, 2019
BUY
$4.9 - $9.31 $56,203 - $106,785
11,470 Added 6.49%
188,082 $1.75 Million
Q1 2019

May 13, 2019
BUY
$4.26 - $6.86 $4,771 - $7,683
1,120 Added 0.64%
176,612 $927,000
Q4 2018

Feb 12, 2019
BUY
$3.6 - $8.42 $9,684 - $22,649
2,690 Added 1.56%
175,492 $781,000
Q3 2018

Nov 14, 2018
SELL
$6.33 - $8.08 $13,134 - $16,766
-2,075 Reduced 1.19%
172,802 $1.4 Million
Q2 2018

Aug 14, 2018
BUY
$6.93 - $14.63 $215,841 - $455,665
31,146 Added 21.67%
174,877 $1.23 Million
Q1 2018

May 09, 2018
SELL
$8.71 - $14.82 $89,451 - $152,201
-10,270 Reduced 6.67%
143,731 $2.05 Million
Q4 2017

Feb 14, 2018
BUY
$7.8 - $12.94 $208,447 - $345,808
26,724 Added 21.0%
154,001 $1.35 Million
Q3 2017

Nov 13, 2017
BUY
$10.9 - $12.73 $1.39 Million - $1.62 Million
127,277
127,277 $1.49 Million

Others Institutions Holding SNDX

# of Institutions
228
Shares Held
88.4M
Call Options Held
1.01M
Put Options Held
692K
View Full List

About Syndax Pharmaceuticals Inc

SNDX Quotes by TradingView
  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $740M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email